Single Chain Antibody for Tumor Imaging
Author Information
Author(s): P. Savage, G. Rowlinson-Buszal, M. Verhoeyen, R.A. Spooner, A. So, J. Windust, P.J. Davis, A.A. Epenetos
Primary Institution: ICRF Tumour Targeting Laboratory, Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital
Hypothesis
The genetically engineered single chain antibody H17E2 can effectively target tumor-associated antigens for improved imaging and therapy.
Conclusion
The H17E2 single chain antibody shows promise for clinical imaging and therapy due to its ability to specifically bind to tumor cells and achieve favorable pharmacokinetics.
Supporting Evidence
- The H17E2 single chain antibody specifically binds to placental alkaline phosphatase, an antigen found in many tumors.
- Compared to whole IgG, the H17E2 SCA achieves superior tumor:blood ratios.
- The study demonstrated that the SCA can be produced economically in bacteria.
- Early trials of a reshaped version of the antibody showed clinical benefits.
- The SCA exhibited rapid blood clearance, which is advantageous for imaging.
- Specific uptake of the SCA was confirmed through competitive binding studies.
- The study highlights the potential for using SCAs in targeted therapy and imaging.
- Optimizing the refolding protocol could improve the yield of functional SCA.
Takeaway
Scientists created a tiny antibody that can find and stick to cancer cells better than regular antibodies, which could help doctors see and treat tumors more effectively.
Methodology
The study involved constructing and expressing a single chain antibody in E. coli, followed by in vivo testing in nude mice with human tumor xenografts.
Limitations
The study had a low yield of purified material and the binding affinity of the single chain antibody was lower than that of the parent IgG.
Participant Demographics
Nude mice bearing human tumor xenografts were used for in vivo testing.
Want to read the original?
Access the complete publication on the publisher's website